The anthracycline antibiotics have now been in use in curative chemotherapy protocols for over two decades. They are highly active against a wide range of haemopoietic and solid tumours in children and adults. Unfortunately, their antineoplastic use is limited by significant and irreversible cardiotoxicity, the full extent of which continues to emerge. As more children become long term survivors of cancer, the relative impact of anthracycline induced cardiac damage has increased but, despite an understanding of the pathogenesis, consensus strategies for detection and prevention have not been established.
Historical perspective Daunorubicin, the first anthracycline antibiotic to be used, was isolated in Italy in 1963 from cultures of Streptomyces peucetius.I In phase II trials it showed activity against acute lymphoblastic leukaemia and acute myeloid leukaemia. Doxorubicin, isolated shortly afterwards,2 showed demonstrable activity against a wider range of tumours in children, including soft tissue and bone sarcomas, Wilms' tumour and lymphomas, as well as lymphoblastic and myeloid leukaemia. Early phase I trials involved patients with widespread disease and reports of cardiotoxicity3 could only uncertainly attribute toxicity to the drug rather than the disease. With increasing use of anthracyclines, however, it became apparent that daunorubicin and doxorubicin were directly cardiotoxic in children4 and adults. 5 Originally cardiac toxicity was described as being acute or subacute and was seen during or immediately after one dose or course of anthracycline. Additionally, late or chronic toxicity occurred after prolonged administration of anthracycline.6 Acute toxicity was seen as transient changes on electrocardiograms, typically ST and T wave flattening, and arrhythmias, typically sinus tachycardia.5 7 These changes usually reverted to normal, were independent of dose, and were mainly seen in adults. The subacute toxicity was manifest as a pericarditismyocarditis syndrome or as acute left ventricular failure6 and was particularly seen in early trials of anthracyclines in adults when scheduling led to doses as high as 160 mg/m2 being delivered over times as short as four days.
Late cardiotoxicity developing after repeated administration of anthracyclines was first recognised when patients presented clinically with symptoms of congestive heart failure5 within six months of their last dose of anthracycline. The outcome was often fatal and necropsy showed the cytoplasmic vacuolisation and myocyte necrosis since recognised as typical of anthracycline damage.5 This review will focus on late toxicity.
Risk factors and incidence
The prime factor determining the risk of developing anthracycline induced cardiomyopathy is the cumulative dose of anthracycline received. Although early studies found no effect of gender, it has been suggested that girls may be at increased risk of cardiotoxicity. 12 The increasing numbers of long term survivors and the availability of routine echocardiography in the late 1 970s meant that reports began to appear of cardiac decompensation occurring for the first time 10 years after initial treatment13 and of subclinical cardiomyopathy.14 Steinherz et al assessed cardiac function by measuring fractional shortening in patients treated in childhood up to 20 years from completing treatment and found an overall 23% incidence of abnormal cardiac function."1 This increased to 63% in the subgroup who had received more than 500 mg/m2 and had been followed up for more than 10 years. Late decompensation as a result of pregnancy or weight training was well recognised. Using more sensitive load independent echocardiographic measures of cardiac function, Lipshultz et al found an overall incidence of 57% abnormalities,10 with up to 15 years' follow up. The full extent of the problem and the functional significance of asymptomatic abnormalities is as yet unclear.
Pathology
Electron microscopic examination of endomyocardial biopsy samples from patients treated with anthracyclines shows myofibril loss, swelling of the sarcoplasmic reticulum and mitochondria, cytoplasmic vacuolisation, and widespread damage with necrosis of myocytes.9
These changes may be focal or diffuse.
The number of myocytes present in the adult heart is established by the age of 6 months. Myocytes lost by necrosis are not replaced, but the remaining myocytes increase in size to compensate. There is also an increase in the amount of interstitial tissue and fibrosis. The changes seen in children and adults are the same.
For The relative cardiotoxicity of idarubicin and aclarubicin A remains to be established although damage is produced by the two drugs.
In an attempt to synthesise an anthracycline analogue without cardiotoxicity the structurally less similar anthraquinone, mitoxantrone, was developed. It has antitumour activity in leukaemias, but again causes cardiac damage with an incidence of 3% of heart failure at cumulative doses greater than 160 mg/M2.32 Antineoplastic doses are also lower than doxorubicin, but there has been no direct comparison of cardiotoxicity for equivalent antineoplastic doses.
Several synthetic anthrapyrazole drugs are currently undergoing evaluation. Their iminoquinine structure should prevent free radical generation, so assessment of their cardiotoxic potential may be promising. Subsequent prospective studies,38 which included examination for subclinical cardiotoxicity, also confirmed the cardioprotective effect of weekly bolus administration for the same dose intensity.
In the belief that the reduced cardiotoxicity of weekly doxorubicin was the result of reduced peak plasma concentrations, other groups investigated enhancing this effect by administering doxorubicin as a prolonged intravenous infusion. Unequivocal data supporting reduced toxicity with prolonged infusions are limited, with much of the work being carried out in adults in small series with historical controls. Some of the most convincing data came from Legha et al at the M D Anderson Center39 where, in a nonrandomised study monitoring changes in endomyocardial biopsy score, reduced cardiotoxicity was seen for the group receiving 24-96 hour infusions as opposed to bolus doses. The infusion time for the prolonged infusion group of 21 patients was escalated in steps from 24 to 96 hours. Five patients were maintained on 48 hour infusions, the remainder at 96 hours making it impossible to ascertain the relative toxicity of the different times, but it seems likely that extending the infusion time to 96 hours is cardioprotective.
Casper et al, in a prospective randomised study, showed using radionuclide angiography that doxorubicin given over 72 hours was less cardiotoxic than bolus injections for a given cumulative dose, but that protection was by no means absolute.40 Two small series with historical controls have suggested that 24 and 48 hour infusions may also be less toxic. 41 42 The original study of Speyer et al of six hour infusions was uncontrolled, but again showed that prolonging doxorubicin infusion time is not absolutely protective, with 48% of patients showing a decrease in ejection fraction of 10% or more.43 This is comparable with the 42% showing a 10% decrease in Casper's study of 72 hour infusions. Subsequently, Shapira et al have confirmed in a controlled trial that six hour infusions are less cardiotoxic than bolus doses. 44 All studies of prolonged anthracycline infusions have been carried out in adults, although feasibility in children has been established in some small paediatric series. No study has examined late cardiotoxicity, nor the relative cardiotoxicity of different infusion times. Most importantly, no study has established how much it is necessary to prolong bolus doses to reduce cardiotoxicity.
An essential correlate of reducing toxicity by increasing infusion times is that antineoplastic efficacy is preserved. In Based on our own analysis of published reports and experience, current practice is as follows:
(1) Doxorubicin and daunorubicin are always administered as infusions with a minimum infusion time of one hour. Some UK/European study treatment protocols request administration times of greater than one hour with which we comply. We have not been involved in studies of prolonged anthracycline infusion.
(2) Standard monitoring is carried out on all patients receiving anthracyclines using electrocardiography and echocardiography. Wherever feasible, baseline assessment takes place before the initiation of treatment; however, because assessment is at another hospital, it is not always possible to do this in seriously ill children. We broadly follow CCSG guidelines28 in that we obtain further echocardiograms or electrocardiograms, or both, before alternate courses of anthracyclines at doses less than 300 mg/im2 and before every course above this dose level.
(3) We use fractional shortening as our main guide to tailoring treatment. A decrease in fractional shortening of more than 10% from baseline or fractional shortening less than 29% will trigger a discussion about further anthracycline treatment. We would usually repeat the test one to two weeks later and discontinue anthracyclines if the result is confirmed.
(4) Our follow up policy after completion of treatment varies depending on the end of treatment cardiac function. In those with a 'normal' or 'acceptable' cardiac function (fractional shortening >29%), echocardiography is carried out at one, three, and five years after the end of treatment and our aim is then to repeat this every five years or sooner if there is any other potential problem -for example, growth hormone treatment or pregnancy. In those with abnormal end of treatment function, echocardiography is carried out between three and six months after the completion of treatment, at one year, and then at least annually for the next five years, although a number of children have required more frequent monitoring.
Conclusions
For paediatric oncologists the use of anthracyclines to treat children with malignancies causes a dilemma. Anthracyclines undoubtedly damage the myocardium irreversibly and an important minority of children have survived their tumour to die of cardiomyopathy. Furthermore, because more than 50% of children with cancer become long term survivors, the fact that 23-57% of those who received anthracyclines have evidence of subclinical myocardial damage has worrying implications for the future. Anthracyclines form an important part of the curative chemotherapy given to children with acute myeloid leukaemia, Wilms' tumour, and sarcomas and may only be discarded at the potential cost of a decrease in survival rates. Cardioprotective strategies require careful controlled clinical trials before they are accepted into routine clinical use.
